AI for Dental Practices in 2026: What's FDA-Cleared, What's Hype, and What's Worth Buying

Dental AI in 2026 splits cleanly into two worlds, and the difference between them matters more than any feature comparison. On one side: FDA-cleared imaging tools that analyze radiographs and suggest clinical findings — regulated medical devices that have been validated for safety and effectiveness. On the other: everything else — front-office automation, patient communication, scheduling, and general-purpose AI — which doesn't need FDA clearance because it isn't making clinical determinations.

Confusing these two categories is the single most common mistake dental practices make when evaluating AI. A tool that analyzes your X-rays and flags caries needs FDA 510(k) clearance. If it doesn't have it, you're either using it off-label or the vendor is making claims they shouldn't. A tool that books appointments or drafts patient emails needs no such clearance, and demanding it would be pointless.

This guide breaks down both worlds: which dental AI tools are actually FDA-cleared, what they detect, real pricing, and a practical framework for evaluating dental AI without falling for marketing. As always, this is informational — verify FDA clearances and compliance directly before deploying any clinical tool.

The two categories of dental AI

Understanding the split is the foundation of every good dental AI decision.

Clinical AI interprets medical images, suggests diagnoses, or supports clinical decisions. This category includes radiograph analysis tools that detect caries, measure bone loss, and identify periapical lesions. Because these tools influence clinical judgment, they're regulated by the FDA as medical devices. The relevant clearance pathway is the FDA 510(k), which validates that a device is safe and effective for its stated indications.

Non-clinical AI handles everything that doesn't make clinical determinations: AI receptionists, scheduling agents, recall automation, billing and coding, patient communication, and practice operations. These tools don't need FDA clearance because they aren't interpreting medical images or suggesting diagnoses. General-purpose AI like ChatGPT and Claude fall here too — they're used at thousands of practices for documentation, marketing, and operations with no clearance needed (though they still require HIPAA compliance and BAAs if they touch patient data).

The practical rule: if a tool analyzes your radiographs and suggests clinical findings, it needs FDA clearance. If it doesn't have clearance, that's a red flag for clinical use and audit defense.

The FDA-cleared imaging tools

As of 2026, five dental AI tools hold FDA 510(k) clearance for clinical imaging use in the United States. Three handle standard 2D radiograph analysis; two cover specialty 3D and orthodontic workflows.

Pearl

Pearl's Second Opinion is one of the most widely adopted FDA-cleared dental imaging platforms. It holds FDA 510(k) clearance K210365 for 2D imaging, plus a separate clearance for 3D. Pearl reports its AI helps clinicians detect 37% more disease across more than 23,000 practices using the platform — a vendor-reported figure, though the FDA clearance itself is independently verifiable.

Pearl's detection coverage includes caries, calculus, periapical findings, and other pathologies. Its design emphasis is real-time chairside assistance: the AI analyzes radiographs during the exam, and the visual overlays help with patient case presentation. Practices specifically value Pearl for reducing interpretation variability between rotating doctors and associates — establishing consistency across recalls and new-patient exams. As of 2026, Pearl holds seven FDA-cleared modules including multi-condition detection in bitewing and periapical images, periodontal bone level measurement, CBCT segmentation, and specialized modules for pediatric caries and periapical lesion contouring.

Pearl's Second Opinion has been listed around $349/month through a third-party partner with no contract required, with volume-based pricing for larger organizations. Verify current pricing directly with the vendor.

Overjet

Overjet is positioned as clinical intelligence infrastructure rather than just a chairside detection tool. It starts with imaging AI and extends into revenue cycle management, enterprise analytics, and multi-location governance — making it especially popular with DSOs and multi-location groups.

Overjet holds FDA 510(k) clearance K222746 for Caries Assist plus additional CBCT Assist clearances. As of 2026, it leads the field with ten FDA-cleared modules covering caries and calculus detection for both pediatric and adult patients, periapical radiolucency, automated dental charting, and image enhancement. Notably, Overjet is the first and only dental AI platform FDA-cleared to enhance images — automatically improving blurry or noisy X-rays without losing clinical detail. No other dental AI platform holds that image enhancement clearance.

Overjet's pricing is customized based on practice size, location count, and selected modules, with a demo required for a quote. Practices report strong ROI from increased production, though specific figures are vendor-reported.

VideaHealth

VideaHealth received FDA clearance in January 2024 covering more than 30 detections, and is known for multi-condition detection across caries, periodontal disease, and other radiographic categories. VideaHealth reports a 119% increase in caries detection and a 20% lift in case acceptance among its users — both vendor-reported figures.

VideaHealth is frequently cited as the strongest option for large multi-location groups (10+ locations), where its enterprise infrastructure and analytics shine. For smaller practices, Pearl or Overjet are often more practical starting points.

Diagnocat and Orca Dental AI

Two additional tools cover specialty workflows: Diagnocat holds FDA clearance for CBCT (3D cone beam) segmentation, and Orca Dental AI is cleared for cephalometric (orthodontic) analysis. These serve narrower use cases than the 2D radiograph tools but are the relevant FDA-cleared options for practices focused on 3D imaging or orthodontics.

What the FDA clearance actually means

It's worth being precise about what "FDA-cleared" does and doesn't mean, because the marketing often blurs it.

FDA 510(k) clearance means the device has been validated for safety and effectiveness for its specific stated indications — it's not experimental technology. FDA-cleared dental imaging platforms now achieve sensitivity comparable to experienced clinicians on many indications. That's a meaningful bar.

But clearance is specific to indications. A tool cleared for caries detection in bitewing images is cleared for that — not necessarily for every type of detection in every image type. This is why the number of cleared modules matters (Overjet's ten vs Pearl's seven), and why you should verify the specific K-number and its stated indications at fda.gov before deploying a tool clinically, especially in a multi-location group where audit defense matters.

The clearance also doesn't mean the AI replaces clinical judgment. These are diagnostic aids — they flag findings for the clinician to confirm. The dentist remains responsible for the diagnosis. The AI's value is catching things a tired clinician might miss and standardizing detection across a team, not replacing the dentist's expertise.

Why this category is worth it (and the honest caveats)

Dental imaging AI is arguably the highest-impact AI category for chairside dentistry in 2026, for two distinct reasons.

Diagnostic accuracy. FDA-cleared platforms catch early-stage caries, subtle bone loss, and periapical findings that are easy to miss on a quick read — especially late in a busy day. The consistency benefit is real: AI doesn't get tired, doesn't rush the last appointment before lunch, and applies the same detection threshold to every image.

Case acceptance. This is the underappreciated driver. When a patient can see the AI-highlighted area of decay on their own X-ray, treatment acceptance rises. The visual overlay turns "trust me, you need this filling" into "here's the problem, highlighted." Vendors report significant case acceptance lifts, and while those figures are vendor-reported, the underlying mechanism — patients accepting treatment they can see — is well-established.

The honest caveats:

Per-chair fees add up. AI imaging add-ons typically cost $100-$500+ per month, and in multi-operatory practices the per-chair math gets material quickly. Calculate the total across all your operatories, not just the per-chair number.

Integration must be verified upfront. Pearl, Overjet, and others publish integrations with Dentrix, Eaglesoft, Open Dental, Curve, and Carestream — but specifics vary by PMS version and imaging platform. Do not take integration claims at face value. Confirm your exact PMS version and sensor setup are supported before signing.

Not every practice needs it today. For a single-provider practice where diagnostic variance is already low, the case for imaging AI is weaker than for a multi-provider group with rotating associates. If your bigger problem is the phone (it is for most practices), the better first investment may be front-office AI, with imaging AI as a later clinical layer.

Vendor outcome numbers are vendor-reported. The "37% more disease," "119% increase in caries detection," and "10x ROI" figures come from vendors. The FDA clearances are independently verifiable; the outcome percentages are not. Treat them as directionally useful, not gospel.

The non-clinical side: front-office AI

Beyond imaging, a growing share of dental AI handles the work that doesn't touch radiographs — and for many practices, this is the more natural entry point because it solves the daily pain of phone tag, no-shows, and recall gaps.

AI receptionists and scheduling agents answer calls, book appointments, handle reschedules, and manage recall outreach. For practices drowning in phone volume, these can be transformative. One important compliance note: AI receptionists with call recording can trigger wiretap claims in two-party-consent states. Confirm your vendor handles consent properly for your state.

Recall and reactivation automation identifies patients overdue for cleanings or treatment and automates outreach. This directly addresses revenue leakage from patients who fall out of the recall cycle.

Billing and coding AI handles CDT/CPT coding, claims, and revenue cycle management. The major practice management platforms (Dentrix Ascend, Eaglesoft, Open Dental, Curve, Carestream, Planet DDS) are increasingly embedding AI modules for scheduling optimization, no-show prediction, treatment plan presentation, and RCM.

General-purpose AI (ChatGPT, Claude) handles patient communication drafts, marketing content, insurance documentation, and hiring — with no FDA clearance needed. The critical caveat: if any patient health information is involved, these require HIPAA compliance and a BAA, which the consumer versions of these tools do not provide. (See our guide to what HIPAA compliance means for AI tools for the full picture.)

A practical evaluation framework

How to actually evaluate dental AI without falling for marketing.

Start with your biggest pain point. If your problem is missed diagnoses or inconsistency between providers, start with imaging AI. If your problem is the phone, no-shows, or recall gaps, start with front-office AI. Don't buy imaging AI to solve a scheduling problem.

For clinical tools, verify the FDA clearance. Get the specific K-number and confirm it at fda.gov. Check that the cleared indications match what you actually need (caries detection, bone loss measurement, CBCT segmentation, etc.). For multi-location groups, this is audit defense, not bureaucracy.

Run a real pilot on your own radiographs. Clinical AI evaluations that don't use your actual practice X-rays and your own clinicians' review are almost always misleading. Insist on a 30-60 day pilot measuring detection changes, time savings, case acceptance improvements, and staff comfort. Pilot data — not vendor demos — should drive the decision.

Verify integration with your exact stack. Confirm your specific PMS version, imaging software, and sensor brand are supported. Integration specifics vary, and a tool that doesn't fit your stack creates workflow friction that erases its value.

Confirm HIPAA compliance and BAA. Every AI vendor with access to PHI is a third-party risk that must be governed under a signed Business Associate Agreement, ideally with subcontractor flow-down clauses. This applies to both clinical and non-clinical tools.

Calculate total cost across all operatories. Per-chair pricing looks small until you multiply by your operatory count. Run the full-practice math before committing.

Don't try to solve everything at once. Approach one use case at a time. Train staff properly before full rollout. Overwhelming your clinical team with multiple new AI tools simultaneously is how adoption fails.

How to choose between Pearl, Overjet, and VideaHealth

For the most common decision — picking among the three leading 2D imaging platforms — here's the practical framing.

Pearl is the strong chairside detection platform. Best for practices that want excellent real-time pathology detection and patient-facing visuals at a transparent price point, without needing enterprise analytics. Its transparent third-party pricing (~$349/month) and no-contract availability make it accessible for solo and small practices.

Overjet is clinical intelligence infrastructure. Best for groups and DSOs that want imaging AI plus revenue cycle management, enterprise analytics, and multi-location governance. Its unique FDA-cleared image enhancement and ten cleared modules give it the deepest clinical feature set. Enterprise pricing, demo required.

VideaHealth is the enterprise multi-location choice. Best for large groups (10+ locations) where its enterprise infrastructure and analytics justify the investment. For smaller practices, Pearl or Overjet are usually more practical.

The standard DSO shortlist is all three — and the right move is to run the same controlled pilot across all of them on your own radiographs rather than evaluating any one in isolation.

The bottom line

Dental AI in 2026 is real, FDA-cleared, and clinically validated for imaging — it's not hype. The FDA-cleared imaging tools (Pearl, Overjet, VideaHealth for 2D; Diagnocat and Orca for specialty workflows) catch disease that's easy to miss, standardize detection across a team, and meaningfully improve case acceptance when patients can see their own findings highlighted. For multi-provider practices and DSOs especially, the case is strong.

But the technology isn't free, not every practice needs it today, and the category split matters enormously. Clinical tools that read your radiographs need FDA clearance — verify it. Non-clinical tools that handle your phones and scheduling don't — but they still need HIPAA compliance if they touch patient data. The practices that win with dental AI are the ones that start with their actual biggest pain point, pilot on their own data, verify the regulatory and compliance details, and roll out one use case at a time rather than chasing every shiny tool at once.

For a directory of dental AI tools — including FDA-cleared imaging platforms and front-office automation — with compliance details and specialty fit, see our solo dental practices page, our AI Medical Imaging & Diagnostics use case page, and our full directory.

This article is informational only and does not constitute medical, legal, or procurement advice. FDA clearances, vendor capabilities, and pricing change frequently, and outcome figures cited are vendor-reported. Always verify FDA 510(k) clearance numbers at fda.gov, confirm HIPAA compliance and BAA availability, and run your own clinical pilot before deploying any AI tool in clinical practice.